ROSEN, LEADING INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Geron securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 12, 2025 [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false and misleading statements regarding the market potential and profitability of its drug RYTELO, which were not disclosed to investors [4] - Key issues include a lack of awareness among healthcare providers, monitoring requirements, seasonality, and competition that would impair Geron's ability to capitalize on the drug's market potential [4] - As a result of these misrepresentations, Geron's business and financial prospects were overstated, leading to investor damages when the true information became public [4]